Agenda - Council - 07/23/1991 - Laserfiche WebLink

Home

~TL V.~/;/~ V - Co.~L,~ [7) Avo~din~ I~a, gn~ncy ufltil more ~ k~)w~ atx~! the flsks of transmitt~g HTLV-I~/ LAV f~ ~t~r to Io~ ~ ~w~ (9) lnfo~i~ physicians. ~entis~. a~ ot~r ap~opnate h~lth ~of~s~ats of his/~r entity s~tus when ~ki~ medi~l care so that the ~tmnt pro~e~ ~aiu, ted. 3. Infected ~tients should ~ enc~raged to mf~ ~x ~ or ~mons with wh~ they have s~er~ ~e~s to their ~alth-care ~r f~ evaluation a~/~ testiS. If ~tients ~efer. trained health ~epe,ment ~rofess~n,ls s~ ~ ma~e avmla~e to assist noticing their pamne~ and counseling them mgl~i~ evaluation a~/~ tasting. 4. Per,ns with a ~ative test ~sult should ~ c~nse~ regarding their ~ for continu~ evaluation to monitor their infection status if t~y c~tmue high-hsk ~hav~ (E). 5. State and local health officials shoutd eval~te the im~ications of r~uin~ the re~rting of m~atedly reactive HTLV-III/~V antib~y test msutts to the s~ate health Oe~,ment. 6. State or local action is appropriate on ~u~lic health grou~s to r~plate or close.establish- ments where there is evi0e~e that they facilitate h~h.~sk ~havio~. s~h as e~nymous ~x~l contacts and/or intercoume with multiple ~,~rs or IV drag a~se le.g., bath- house, houses of prostitution. 'shooting TEST INTERPR~ATION Commercially available tests to detect anti~y to HTLV-III/LAV are enzyme-link~ immu- noso~nt assays [EUSAs} usi~ antigens ~env~ from disrupted HTLV-ill/LAV. When the E~A is reactive on initial testing, it is sta~a~ ~um to re,at the t~t ~ the same s~men. Re~at~ly reactive tests are hig~ ~sitwe a~ s~cific f~ HTLV-ilI/~V ant~- ~. ~wever. since fat~ty ~sitive tests ~c~. a~ the implications of a ~sitive test are seh~. additional m~e s~cific tests te.g.. West~ b~L immu~flu~e~ent ashy. e~c.) are r~om~n~ fol~wing m~at~iy reactive E~SA results, es~cialN in Iow-~vale~e la~. ~ additional more s~ific test results are ~t m~ily available. ~ns in high-risk g~ with stmn9 m~a~ty mact~e EUSA ~ts can ~ c~n~ ~f~e any ~diti~al test ~lts are r~ ~a~i~ their ~o~b~ inf~t~ status, the~ ~ f~ m~ical fol~w-u~, a~ ways to ~uce fu~her transmiss~n of HTLV-III/~V. ~HER CONSIDE~TIONS sham ~s with ~ns w~ am HTLVqlU~-anti~ ~sit~e will ~. ~e~i~ on s~te a~ I~al s~t~ th,t ~h~ze s~h ac~ Acc~ishi~ the oboe of i~ ~ission by e~r~i~ testi~ a~ co~li~ amo~ ~ns in h~h-h~ grou~s wi~ ~ heevi~ ~ health officials ~yi~ ~f~ a~t~ to mainta~n~ c~f~tiality T~ ~lic health effectives of van~s a~aches to counseli~. ~x-pa,~ rare,al. I~ ~to~ testi~ will ~uire careful momt~. The feesibili~ a~ effica~ of each of t~ ~asures shou~ ~ ~ai~t~ by s;ate a~ I~al health 0e~a,ments to ~St utilize ave~ resoumas. . 1. ~ ~, M~ WM, Hm~y ~. Jeffe HW, D~ ~. ~ WR. The e~~y of AJ~S: cun,~t stitus e~d fut~'~ I~OSp4Ct~. ~ t985;229: 1352-7. ~. RKommKItm~ f~ ~~ ~m~sm of ~ Mth hum~ T-~oho~ ~ ~ymO~at~y-ass~t~ ~s ~ l~e ~e. M~R 1985;34:682-6. 691 ~. U~III: Kq~r~ ~m~et~c~y Sy~rO~ ~ the Sen F~co co~ stay. 1978-1985. MMWE 1985;34:573-5.